Rebecca Jane Cox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rebecca Jane Cox has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Eva Mykkeltvedt
Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway
2 shared publicationsLars R Haaheim
Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway
2 shared publicationsArnt-Ove Hovden
Influenza Centre, The Gade Institute, University of Bergen, Gades Institute Thormohlens gt 55, N-5020 Bergen, Norway
1 shared publicationE. Mykkeltvedt
Department of Molecular Biology
1 shared publicationHåkon Sjursen
Department of Infectious Diseases, Haukeland Hospital, University of Bergen, N-5020 Bergen, Norway
1 shared publicationInger Marie Haaland
Influenza Centre, The Gade Institute, University of Bergen, Gades Institute Thormohlens gt 55, N-5020 Bergen, Norway
1 shared publication
Latest Publications
- 1 June 2004
- Published by Elsevier in International Congress Series
- Vol. 1263, 632-635
Comparison of the humoral immune response to split and whole virus vaccines in mice
- 1 June 2004
- Published by Elsevier in International Congress Series
- Vol. 1263, 632-635
Comparison of the humoral immune response to split and whole virus vaccines in mice
- Open Access
- 16 January 2004
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 59 (1) , 1-15
Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines
Influenza virus is a globally important respiratory pathogen which causes a high degree of morbidity and mortality annually. The virus is continuously undergoing antigenic change and thus bypasses the host's acquired immunity to influenza. Despite the improvement in antiviral therapy during the last decade, vaccination is still the most effective method of prophylaxis. Vaccination induces a good degree of protection (60–90% efficacy) and is well tolerated by the recipient. For those at risk of complications from influenza, annual vaccination is recommended due to the antigenic changes in circulating strains. However, there is still room for improvement in vaccine efficacy, long‐lasting effect, ease of administration and compliance rates. The mucosal tissues of the respiratory tract are the main portal entry of influenza, and the mucosal immune system provides the first line of defence against infection. Secretory immunoglobulin A (SIgA) and IgM are the major neutralizing antibodies directed against mucosal pathogens. These antibodies work to prevent pathogen entry and can function intracellularly to inhibit replication of virus. This review describes influenza virus infection, epidemiology, clinical presentation and immune system response, particularly as it pertains to mucosal immunity and vaccine use. Specifically, this review provides an update of the current status on influenza vaccination and concentrates on the two main types of influenza vaccines currently in use, namely the cold‐adapted vaccine (CAV) given intranasally/orally, and the inactivated vaccine (IV) delivered subcutanously or intramuscularly. The commercially available trivalent IV (TIV) elicits good serum antibody responses but induces poorly mucosal IgA antibody and cell‐mediated immunity. In contrast, the CAV may elicit a long‐lasting, broader immune (humoral and cellular) response, which more closely resembles natural immunity. The immune response induced by these two vaccines will be compared in this review.
- 16 January 2004
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 59 (1) , 1-15
Open AccessInfluenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines
Influenza virus is a globally important respiratory pathogen which causes a high degree of morbidity and mortality annually. The virus is continuously undergoing antigenic change and thus bypasses the host's acquired immunity to influenza. Despite the improvement in antiviral therapy during the last decade, vaccination is still the most effective method of prophylaxis. Vaccination induces a good degree of protection (60–90% efficacy) and is well tolerated by the recipient. For those at risk of complications from influenza, annual vaccination is recommended due to the antigenic changes in circulating strains. However, there is still room for improvement in vaccine efficacy, long‐lasting effect, ease of administration and compliance rates. The mucosal tissues of the respiratory tract are the main portal entry of influenza, and the mucosal immune system provides the first line of defence against infection. Secretory immunoglobulin A (SIgA) and IgM are the major neutralizing antibodies directed against mucosal pathogens. These antibodies work to prevent pathogen entry and can function intracellularly to inhibit replication of virus. This review describes influenza virus infection, epidemiology, clinical presentation and immune system response, particularly as it pertains to mucosal immunity and vaccine use. Specifically, this review provides an update of the current status on influenza vaccination and concentrates on the two main types of influenza vaccines currently in use, namely the cold‐adapted vaccine (CAV) given intranasally/orally, and the inactivated vaccine (IV) delivered subcutanously or intramuscularly. The commercially available trivalent IV (TIV) elicits good serum antibody responses but induces poorly mucosal IgA antibody and cell‐mediated immunity. In contrast, the CAV may elicit a long‐lasting, broader immune (humoral and cellular) response, which more closely resembles natural immunity. The immune response induced by these two vaccines will be compared in this review.
- Open Access
- 1 January 2002
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 55 (1) , 14-23
Non‐Lethal Viral Challenge of Influenza Haemagglutinin and Nucleoprotein DNA Vaccinated Mice Results in Reduced Viral Replication
Influenza DNA vaccines have been widely studied in experimental animal models and protection documented after lethal viral challenge. In this study, we have investigated the humoral response after a non‐lethal viral challenge of mice vaccinated with plasmids encoding the influenza haemagglutinin (HA) or nucleoprotein (NP) genes. BALB/c mice were immunized intramuscularly with three doses (100 µg) of HA, NP or backbone plasmid at 3‐week intervals, or alternatively infected intranasally, before being challenged with homologous virus 13 weeks later. Mice were then sacrificed at weekly intervals and the antibody‐secreting cell response was examined systemically (spleen and bone marrow) and in the respiratory tract (nasal associated lymphoid tissue (NALT) and lungs). Sera were collected after each dose of vaccine and at sacrifice and analyzed by ELISA, haemagglutination inhibition and virus neutralization assays. We found that previous viral infection apparently elicits sterilizing immunity. Vaccination with HA or NP DNA significantly reduced viral replication in the nasal cavity after viral challenge, however, increases in serum antibody titres were observed after challenge. Prior to challenge, specific antibody‐secreting cells were observed in the systemic compartment after HA or NP DNA vaccination but were also found in the NALT after viral challenge. In conclusion, intramuscular DNA vaccination resulted in immunological memory in the systemic compartment, which was rapidly reactivated upon viral challenge.
- 1 January 2002
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 55 (1) , 14-23
Open AccessNon‐Lethal Viral Challenge of Influenza Haemagglutinin and Nucleoprotein DNA Vaccinated Mice Results in Reduced Viral Replication
Influenza DNA vaccines have been widely studied in experimental animal models and protection documented after lethal viral challenge. In this study, we have investigated the humoral response after a non‐lethal viral challenge of mice vaccinated with plasmids encoding the influenza haemagglutinin (HA) or nucleoprotein (NP) genes. BALB/c mice were immunized intramuscularly with three doses (100 µg) of HA, NP or backbone plasmid at 3‐week intervals, or alternatively infected intranasally, before being challenged with homologous virus 13 weeks later. Mice were then sacrificed at weekly intervals and the antibody‐secreting cell response was examined systemically (spleen and bone marrow) and in the respiratory tract (nasal associated lymphoid tissue (NALT) and lungs). Sera were collected after each dose of vaccine and at sacrifice and analyzed by ELISA, haemagglutination inhibition and virus neutralization assays. We found that previous viral infection apparently elicits sterilizing immunity. Vaccination with HA or NP DNA significantly reduced viral replication in the nasal cavity after viral challenge, however, increases in serum antibody titres were observed after challenge. Prior to challenge, specific antibody‐secreting cells were observed in the systemic compartment after HA or NP DNA vaccination but were also found in the NALT after viral challenge. In conclusion, intramuscular DNA vaccination resulted in immunological memory in the systemic compartment, which was rapidly reactivated upon viral challenge.
- 31 October 2001
- Published by Elsevier in International Congress Series
- Vol. 1219, 897-903
DNA vaccination with HA or NP encoding plasmids results in rapid viral clearance after viral challenge
- 31 October 2001
- Published by Elsevier in International Congress Series
- Vol. 1219, 897-903
DNA vaccination with HA or NP encoding plasmids results in rapid viral clearance after viral challenge